This company listing is no longer active
Galapagos Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Paul Stoffels
Chief executive officer
€2.0m
Total compensation
| CEO salary percentage | 38.05% |
| CEO tenure | 2yrs |
| CEO ownership | n/a |
| Management average tenure | 2yrs |
| Board average tenure | 2yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | €2m | €750k | -€4m |
| Sep 30 2023 | n/a | n/a | -€153m |
| Jun 30 2023 | n/a | n/a | -€157m |
| Mar 31 2023 | n/a | n/a | -€181m |
| Dec 31 2022 | €1m | €563k | -€71m |
Compensation vs Market: Paul's total compensation ($USD2.10M) is above average for companies of similar size in the MX market ($USD779.49K).
Compensation vs Earnings: Paul's compensation has increased whilst the company is unprofitable.
CEO
Paul Stoffels (61 yo)
Dr. Paulus A. Stoffels, also known as Paul, Ph.D. M.D. is Chief Executive Officer of Galapagos NV since April 01, 2022 and also serves as its Chairman since April 26, 2022 and also serves as its Interim He...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, Chairman | 2yrs | €1.97m | no data | |
| Executive VP | less than a year | no data | no data | |
| Head of Investor Relations | no data | no data | no data | |
| Executive VP & General Counsel | no data | no data | no data | |
| Head of Corporate Communication | no data | no data | no data | |
| Executive VP & Chief Human Resources Officer | no data | no data | no data | |
| Head of Development | no data | no data | no data | |
| Senior VP & Head of Business Development | 2.3yrs | no data | no data | |
| Head of Development Operations | no data | no data | no data | |
| Head of Medical Affairs | no data | no data | no data | |
| Head of Small Molecules Discovery & Senior VP | 1.8yrs | no data | no data | |
| Senior VP & Head of Immunology Therapeutic Area | 2.3yrs | no data | no data |
Experienced Management: GLPG N's management team is considered experienced (2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, Chairman | 2yrs | €1.97m | no data | |
| Independent Non-Executive Director | less than a year | €32.37k | 0.00027% MX$ 89.9k | |
| Lead Independent Non-Executive Director | 2yrs | €150.00k | 0.0015% MX$ 509.2k | |
| Non-Executive Non-Independent Director | less than a year | no data | no data | |
| Non-Executive Non-Independent Director | 4.5yrs | no data | no data | |
| Non-Executive Independent Director | less than a year | €59.85k | 0.00055% MX$ 183.0k | |
| Independent Non-Executive Director | 5yrs | €115.00k | 0.0030% MX$ 1.0m | |
| Independent Non-Executive Director | 4yrs | €138.75k | 0.0029% MX$ 951.8k | |
| Non-Executive Independent Director | 2yrs | €117.36k | 0.0015% MX$ 502.5k |
Experienced Board: GLPG N's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/04/14 05:10 |
| End of Day Share Price | 2024/01/16 00:00 |
| Earnings | 2023/12/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Lakefront Biotherapeutics NV is covered by 29 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Emily Field | Barclays |
| Xue Chen | Barclays |
| James Gordon | Barclays |